Search

Insmed

Fermé

SecteurSoins de santé

123.69 -1.83

Résumé

Variation du prix de l'action

24h

Actuel

Min

122.2

Max

126

Chiffres clés

By Trading Economics

Revenu

150M

-13M

Ventes

120M

425M

BPA

-0.52

Marge bénéficiaire

-3.112

Employés

1,664

EBITDA

150M

14M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+59.15% upside

Dividendes

By Acuity

Prochains Résultats

29 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.1B

29B

Ouverture précédente

125.52

Clôture précédente

123.69

Sentiment de l'Actualité

By Acuity

40%

60%

138 / 340 Classement par Healthcare

Insmed Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 19:36 UTC

Insmed Inc shares are lower, reflecting broader market sentiment after a reported decline in retail sales. The stock has closed lower for four consecutive sessions.

13 août 2026, 19:51 UTC

News
Social Media

Insmed shares are lower despite raised earnings estimates and target price increases from HC Wainwright and Wells Fargo during Thursday's session.

12 août 2026, 19:36 UTC

News

Insmed shares are trading lower despite multiple analysts issuing positive ratings and target price increases, including BMO's $192.00 and Cantor Fitzgerald's $235.00.

11 août 2026, 21:16 UTC

Insmed Inc. shares moved slightly lower during after-market hours, remaining near the upper end of their one-month range and above the 20-day moving average.

10 août 2026, 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

7 août 2026, 21:21 UTC

Insmed Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

6 août 2026, 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

5 août 2026, 23:22 UTC

Insmed Inc shares are higher in after-market trading, reflecting positive momentum amid a significant drop in crude oil prices and easing inflation concerns.

3 août 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 juil. 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 juil. 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 juil. 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 juil. 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 juil. 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 juil. 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 juil. 2026, 17:41 UTC

Social Media
News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 juil. 2026, 19:16 UTC

News
Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Comparaison

Variation de prix

Insmed prévision

Objectif de Prix

By TipRanks

59.15% hausse

Prévisions sur 12 Mois

Moyen 201.06 USD  59.15%

Haut 243 USD

Bas 169 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

19

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

138 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat